FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:1808-1809 October 29, 2009 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by McHutchison, J. G. PubMed Citation

To the Editor: McHutchison et al. (Aug. 6 issue)¹ report a similar rate of sustained virologic response among patients who received low-dose peginterferon alfa-2b plus ribavirin and patients who received other regimens. Although the groups of patients who received ribavirin plus either peginterferon alfa-2a or standard-dose peginterferon alfa-2b had a more favorable decrease in on-treatment viral loads than the group that received low-dose peginterferon alfa-2b plus ribavirin, the higher relapse rates among the former groups undermined the beneficial viral kinetic response between week 4 and week 48 of therapy. In addition, some data indicated that low-dose peginterferon alfa-2b reduced the . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.